PCN99 Cost-Effectiveness Evaluation of Sunitinib as First-Line Targeted Therapy for Metastatic Renal Cell Carcinoma in Kazakhstan

Kostyuk, A.; Nurgozhin, T.; Mazhitov, T.; Almadiyeva, A.

NUR Home
→
02.National Laboratory Astana
→
Center for Life Sciences
→
Research Institute of Experimental and Clinical Pharmacology and Pharmacy
→
View Item

dc.contributor.author	Kostyuk, A.
dc.contributor.author	Nurgozhin, T.
dc.contributor.author	Mazhitov, T.
dc.contributor.author	Almadiyeva, A.
dc.creator	A., Kostyuk
dc.date.accessioned	2017-12-14T04:54:01Z
dc.date.available	2017-12-14T04:54:01Z
dc.date.issued	2014-05-01
dc.identifier	DOI:10.1016/j.jval.2014.03.494
dc.identifier.citation	A. Kostyuk, T. Nurgozhin, T. Mazhitov, A. Almadiyeva, PCN99 - Cost-Effectiveness Evaluation of Sunitinib as First-Line Targeted Therapy for Metastatic Renal Cell Carcinoma in Kazakhstan, In Value in Health, Volume 17, Issue 3, 2014, Page A85
dc.identifier.issn	10983015
dc.identifier.uri	https://www.sciencedirect.com/science/article/pii/S1098301514005452
dc.identifier.uri	http://nur.nu.edu.kz/handle/123456789/2888
dc.relation.ispartof	Value in Health
dc.title	PCN99 Cost-Effectiveness Evaluation of Sunitinib as First-Line Targeted Therapy for Metastatic Renal Cell Carcinoma in Kazakhstan
dc.type	Article
dc.rights.license	Copyright © 2014 Published by Elsevier Inc.
dcterms.publisher	Value in Health
elsevier.identifier.doi	10.1016/j.jval.2014.03.494
elsevier.identifier.eid	1-s2.0-S1098301514005452
elsevier.identifier.pii	S1098-3015(14)00545-2
elsevier.volume	17
elsevier.issue.identifier	3
elsevier.issue.name	ISPOR 19th Annual International Meeting Research Abstracts
elsevier.coverdate	2014-05-01
elsevier.coverdisplaydate	May 2014
elsevier.startingpage	A85
elsevier.openaccess	1
elsevier.openaccessarticle	true
elsevier.openarchivearticle	true
elsevier.openaccessuserlicense	http://www.elsevier.com/open-access/userlicense/1.0/
elsevier.aggregationtype	Journal